Get Started in Minutes
How Hyqvia Copay Assistance Works
1 – Check Your Coverage/Benefits Verification
Our team of expert billers finds the best avenues of coverage that minimize out-of-pocket costs.
2 – Transfer Prescription to AmeriPharma
We process your prescription by working with your previous pharmacy or prescriber, making the transition quick and easy.
3 – Prior Authorization
Our team of specialists obtains approval from your insurance companies within 24 to 72 hours.
4 – Copay Assistance & Financial Aid
We secure financial aid and decrease copays, out-of-pocket expenses, and high deductibles. To date, AmeriPharma Specialty Care has secured $55 million in financial assistance for our patients.
5 – Nursing Care Coordination
AmeriPharma puts your schedule and home environment first when scheduling and coordinating one of our specialized nurses for your in-home infusions.
6 – Delivery Coordination
Medications are always delivered in strict compliance with the specific requirements for immune globulin shipping. Next-day and overnight cold-chain deliveries are coordinated around your schedule.
What Is Hyqvia?
Hyqvia is an injectable drug containing a genetically designed protein. It is a dual vial unit with a vial of immune globulin infusion 10% (Ig) and another vial of recombinant human hyaluronidase (Hy), which assists your body in the absorption of injectable medicines.
The parts are infused one after the other (Hy first, Ig second) through a needle set.
Hyqvia is an immune globulin infusion. It is a sterilized solution made up of human plasma containing antibodies that help your body protect itself against different infectious diseases. It is used in treating primary immunodeficiency in adults.
Hyqvia is administered in the form of a subcutaneous infusion, given under the skin. It has flexible administration options, and a healthcare provider can teach you how to self-administer in the comfort of your own home.
Do not self-administer the medication if you do not understand the instructions properly. The infusion can also be administered at an infusion center.
What Is Hyqvia Used To Treat?
Hyqvia is mainly indicated for treating primary immunodeficiency (PI) in adults.
Immunodeficiency conditions may include common variable immunodeficiency, Wiskott-Aldrich syndrome, congenital or X-linked agammaglobulinemia, and severe combined immunodeficiencies.
Warnings and Precautions
Hyqvia can cause blood clots, especially if you are 65 years or older, have heart disease, circulation disease, or a history of blood clots.
Immediately contact your provider if you experience sudden chest pain, numbness, slurred speech, vision disorder, shortness of breath or pain, warmth, or swelling in the leg or arm.
Inform your health care professional before administering infusion if you have any other health conditions such as diabetes, kidney disease, pregnancy, or dehydration. Do not infuse into or around an infected area as it may cause the infection to spread.
Copay and Financial Assistance
AmeriPharma Specialty Care alleviates financial burdens for patients and their families
Advanced software locates funding sources to match you with top-dollar foundation programs
One of our copay assistance specialists will assist with the application process
Automatic updates will be sent to you and your physician on the status of the funding
Hyqvia Side Effects
Common side effects of Hyqvia include:
- Antibody formation against hyaluronidase
- Symptoms of allergy such as swelling, itching, pain, and skin rash
Adverse effects that require medical attention:
- Speech and vision problems
- Sudden numbness and lethargy
- Chest pain
- Blood in cough
- Dark urine
- Decreased urination
- Fast heartbeat
- Blood clotting in arm or leg
- Pulmonary disease such as transfusion-related acute lung injury (TRALI)
The dosing of Hyqvia is on an individualized basis.
Hyqvia dosing variations are discussed below:
- If the patient already takes Ig infusions, the treatment should be initiated 1 week after the last Ig infusion.
- Gradually increase dosage and frequency from a 1-week dose to a 3 or 4-week dose.
- The initial dose is 7.5 g on week 1, 15 g on week 2, 22.5 g on week 4, then 30 g on week 7 (full information is available in the Hyqvia package insert).
- If the patient has switched from IVIG treatment, then administer Hyqvia at the same dose and frequency as the previous IV treatment after initial dose ramp-up.
- If the patient has switched from SCIG treatment or is IgG-naïve, then administer at 300 – 600 mg/kg at 3 to 4 week intervals after initial ramp-up.
- If the patient is at high risk of renal failure or thrombosis, then administer Hyqvia at the minimum dose and infusion rate practicable.
Volume Per Site:
Up to 600 ml per site can be administered for patients who weigh 40 kg or more and up to 300 ml per site can be administered for those who weigh less than 40 kg.